RenovaCare, Inc. (RCAR)
USD 0.0
(-50.0%)
USD 0.0
(-50.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2022 | - USD | 100.0% |
| 2021 | -5.4 Million USD | 44.1% |
| 2020 | -9.67 Million USD | -162.23% |
| 2019 | -3.69 Million USD | -83.78% |
| 2018 | -2 Million USD | 25.51% |
| 2017 | -2.69 Million USD | -42.02% |
| 2016 | -1.89 Million USD | -43.97% |
| 2015 | -1.31 Million USD | 38.14% |
| 2014 | -2.13 Million USD | -239.1% |
| 2013 | -628.54 Thousand USD | -157.64% |
| 2012 | -243.95 Thousand USD | 69.22% |
| 2011 | -792.59 Thousand USD | -104.8% |
| 2010 | -387 Thousand USD | 39.52% |
| 2009 | -639.9 Thousand USD | -128.99% |
| 2008 | -279.44 Thousand USD | -912.12% |
| 2007 | -27.61 Thousand USD | 66.7% |
| 2006 | -82.9 Thousand USD | -17.24% |
| 2005 | -70.71 Thousand USD | 59.97% |
| 2004 | -176.63 Thousand USD | 74.95% |
| 2003 | -705.03 Thousand USD | -153.68% |
| 2002 | -277.92 Thousand USD | 21.51% |
| 2001 | -354.09 Thousand USD | 58.74% |
| 2000 | -858.15 Thousand USD | -14.73% |
| 1999 | -747.99 Thousand USD | -146.92% |
| 1998 | -302.93 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 Q3 | - USD | 0.0% |
| 2023 Q2 | - USD | 0.0% |
| 2023 Q1 | - USD | 0.0% |
| 2022 FY | - USD | 100.0% |
| 2022 Q3 | -1.87 Million USD | 11.81% |
| 2022 Q1 | -1.72 Million USD | 17.22% |
| 2022 Q4 | - USD | 100.0% |
| 2022 Q2 | -2.12 Million USD | -23.25% |
| 2021 Q4 | -2.08 Million USD | -22.68% |
| 2021 Q1 | -517.24 Thousand USD | 79.81% |
| 2021 Q3 | -1.7 Million USD | -53.84% |
| 2021 Q2 | -1.1 Million USD | -113.7% |
| 2021 FY | -5.4 Million USD | 44.1% |
| 2020 Q2 | -3.04 Million USD | -147.85% |
| 2020 Q4 | -2.56 Million USD | 9.9% |
| 2020 FY | -9.67 Million USD | -162.23% |
| 2020 Q3 | -2.84 Million USD | 6.62% |
| 2020 Q1 | -1.22 Million USD | 1.1% |
| 2019 Q3 | -1.2 Million USD | -86.59% |
| 2019 Q2 | -643.52 Thousand USD | -6.55% |
| 2019 Q4 | -1.24 Million USD | -3.44% |
| 2019 FY | -3.69 Million USD | -83.78% |
| 2019 Q1 | -603.97 Thousand USD | -9.26% |
| 2018 FY | -2 Million USD | 25.51% |
| 2018 Q3 | -432.49 Thousand USD | 3.77% |
| 2018 Q2 | -449.43 Thousand USD | 21.79% |
| 2018 Q4 | -552.78 Thousand USD | -27.81% |
| 2018 Q1 | -574.66 Thousand USD | 21.57% |
| 2017 Q4 | -732.7 Thousand USD | -27.48% |
| 2017 FY | -2.69 Million USD | -42.02% |
| 2017 Q3 | -574.74 Thousand USD | 42.88% |
| 2017 Q2 | -1 Million USD | -163.35% |
| 2017 Q1 | -382.1 Thousand USD | -19.35% |
| 2016 Q2 | -527.35 Thousand USD | 32.47% |
| 2016 Q4 | -320.14 Thousand USD | -18.92% |
| 2016 Q3 | -269.21 Thousand USD | 48.95% |
| 2016 Q1 | -780.89 Thousand USD | -44.52% |
| 2016 FY | -1.89 Million USD | -43.97% |
| 2015 Q3 | -297.03 Thousand USD | -37.56% |
| 2015 Q1 | -265.19 Thousand USD | -4.47% |
| 2015 Q2 | -215.93 Thousand USD | 18.58% |
| 2015 FY | -1.31 Million USD | 38.14% |
| 2015 Q4 | -540.34 Thousand USD | -81.92% |
| 2014 Q1 | -268.02 Thousand USD | 10.49% |
| 2014 FY | -2.13 Million USD | -239.1% |
| 2014 Q4 | -253.84 Thousand USD | 80.1% |
| 2014 Q3 | -1.27 Million USD | -282.35% |
| 2014 Q2 | -333.68 Thousand USD | -24.5% |
| 2013 Q3 | -184.86 Thousand USD | -121.77% |
| 2013 FY | -628.54 Thousand USD | -157.64% |
| 2013 Q2 | -83.35 Thousand USD | -18.45% |
| 2013 Q4 | -299.44 Thousand USD | -61.98% |
| 2013 Q1 | -70.37 Thousand USD | -59.1% |
| 2012 FY | -243.95 Thousand USD | 69.22% |
| 2012 Q2 | -77.93 Thousand USD | 6.38% |
| 2012 Q1 | -83.25 Thousand USD | 62.75% |
| 2012 Q3 | -38.53 Thousand USD | 50.56% |
| 2012 Q4 | -44.23 Thousand USD | -14.78% |
| 2011 Q2 | -230.8 Thousand USD | -57.1% |
| 2011 Q1 | -146.91 Thousand USD | 5.11% |
| 2011 Q3 | -191.37 Thousand USD | 17.08% |
| 2011 Q4 | -223.5 Thousand USD | -16.79% |
| 2011 FY | -792.59 Thousand USD | -104.8% |
| 2010 FY | -387 Thousand USD | 39.52% |
| 2010 Q4 | -154.82 Thousand USD | -114.35% |
| 2010 Q1 | -105.14 Thousand USD | -42.71% |
| 2010 Q2 | -54.8 Thousand USD | 47.88% |
| 2010 Q3 | -72.23 Thousand USD | -31.79% |
| 2009 Q4 | -73.67 Thousand USD | 57.49% |
| 2009 Q3 | -173.29 Thousand USD | 35.0% |
| 2009 Q2 | -266.6 Thousand USD | -111.04% |
| 2009 Q1 | -126.32 Thousand USD | 2.91% |
| 2009 FY | -639.9 Thousand USD | -128.99% |
| 2008 FY | -279.44 Thousand USD | -912.12% |
| 2008 Q1 | -14.8 Thousand USD | -110.79% |
| 2008 Q2 | -17.08 Thousand USD | -15.36% |
| 2008 Q4 | -130.11 Thousand USD | -10.52% |
| 2008 Q3 | -117.72 Thousand USD | -589.28% |
| 2007 Q2 | -9102.00 USD | -43.32% |
| 2007 Q4 | -7024.00 USD | -36.84% |
| 2007 Q3 | -5133.00 USD | 43.61% |
| 2007 FY | -27.61 Thousand USD | 66.7% |
| 2007 Q1 | -6351.00 USD | 75.33% |
| 2006 Q1 | -10.42 Thousand USD | 64.32% |
| 2006 FY | -82.9 Thousand USD | -17.24% |
| 2006 Q4 | -25.74 Thousand USD | -42.07% |
| 2006 Q3 | -18.11 Thousand USD | 36.69% |
| 2006 Q2 | -28.61 Thousand USD | -174.39% |
| 2005 Q1 | -6302.00 USD | -358.6% |
| 2005 Q2 | -10.88 Thousand USD | -72.77% |
| 2005 Q3 | -21.03 Thousand USD | -93.16% |
| 2005 Q4 | -29.23 Thousand USD | -39.0% |
| 2005 FY | -70.71 Thousand USD | 59.97% |
| 2004 Q1 | -82.01 Thousand USD | 41.38% |
| 2004 Q2 | -52.03 Thousand USD | 36.55% |
| 2004 FY | -176.63 Thousand USD | 74.95% |
| 2004 Q4 | 2437.00 USD | 105.41% |
| 2004 Q3 | -45.01 Thousand USD | 13.49% |
| 2003 Q1 | -206.11 Thousand USD | 54.53% |
| 2003 Q2 | -188.38 Thousand USD | 8.6% |
| 2003 FY | -705.03 Thousand USD | -153.68% |
| 2003 Q4 | -139.92 Thousand USD | 17.99% |
| 2003 Q3 | -170.61 Thousand USD | 9.43% |
| 2002 Q4 | -453.33 Thousand USD | -811.04% |
| 2002 Q2 | 97.48 Thousand USD | 588.04% |
| 2002 Q1 | 14.16 Thousand USD | 107.79% |
| 2002 FY | -277.92 Thousand USD | 21.51% |
| 2002 Q3 | 63.75 Thousand USD | -34.6% |
| 2001 Q4 | -181.88 Thousand USD | -279.83% |
| 2001 Q1 | -171.48 Thousand USD | 49.53% |
| 2001 FY | -354.09 Thousand USD | 58.74% |
| 2001 Q3 | -47.88 Thousand USD | -15.06% |
| 2001 Q2 | -41.62 Thousand USD | 75.73% |
| 2000 Q1 | -200.38 Thousand USD | 0.0% |
| 2000 Q2 | -180.77 Thousand USD | 9.79% |
| 2000 FY | -858.15 Thousand USD | -14.73% |
| 2000 Q3 | -137.22 Thousand USD | 24.09% |
| 2000 Q4 | -339.76 Thousand USD | -147.59% |
| 1999 FY | -747.99 Thousand USD | -146.92% |
| 1998 FY | -302.93 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | 100.0% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 100.0% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 100.0% |
| Nascent Biotech, Inc. | -2.22 Million USD | 100.0% |
| Rebus Holdings, Inc. | -664 Thousand USD | 100.0% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 100.0% |
| Qrons Inc. | -643.67 Thousand USD | 100.0% |
| Adynxx, Inc. | - USD | NaN% |
| Neon Bloom, Inc. | -389.57 Thousand USD | 100.0% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 100.0% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 100.0% |
| Skye Bioscience, Inc. | -13.67 Million USD | 100.0% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 100.0% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 100.0% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | 100.0% |
| SQZ Biotechnologies Company | -75.82 Million USD | 100.0% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 100.0% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 100.0% |
| Mesoblast Limited | -84.14 Million USD | 100.0% |
| Marizyme, Inc. | -34.08 Million USD | 100.0% |
| Genus plc | 6.4 Million USD | 100.0% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 100.0% |
| Pharming Group N.V. | -4.87 Million USD | 100.0% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 100.0% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | 100.0% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 100.0% |
| ContraFect Corporation | -56.88 Million USD | 100.0% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 100.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | NaN% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 100.0% |
| IMV Inc. | -38.67 Million USD | 100.0% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 100.0% |
| MultiCell Technologies, Inc. | -722.81 USD | 100.0% |
| ONE Bio Corp. | 13.68 Million USD | 100.0% |
| Accustem Sciences Inc. | -3.74 Million USD | 100.0% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 100.0% |
| Arno Therapeutics, Inc. | - USD | NaN% |
| EV Biologics, Inc. | -483.06 Thousand USD | 100.0% |
| Q BioMed Inc. | -3.44 Million USD | 100.0% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 100.0% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 100.0% |
| Biomind Labs Inc. | -1 Million USD | 100.0% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 100.0% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 100.0% |
| TetraLogic Pharmaceuticals Corporation | - USD | NaN% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 100.0% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 100.0% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | 100.0% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 100.0% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 100.0% |
| GB Sciences, Inc. | -1.42 Million USD | 100.0% |
| Alpha Cognition Inc. | -9.7 Million USD | 100.0% |
| HST Global, Inc. | -140.9 Thousand USD | 100.0% |
| CSL Limited | 3.7 Billion USD | 100.0% |
| Wesana Health Holdings Inc. | -1.12 Million USD | 100.0% |
| Halberd Corporation | -75.05 Thousand USD | 100.0% |
| Enzolytics Inc. | -2.14 Million USD | 100.0% |
| Agentix Corp. | -1.37 Million USD | 100.0% |
| Resverlogix Corp. | -12.74 Million USD | 100.0% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 100.0% |
| MetaStat, Inc. | - USD | NaN% |
| argenx SE | -425.04 Million USD | 100.0% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | 100.0% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 100.0% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | 100.0% |
| GeneThera, Inc. | - USD | NaN% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 100.0% |
| AVAX Technologies, Inc. | 6.69 Million USD | 100.0% |
| Zenith Capital Corp. | -8.94 Million USD | 100.0% |
| Genscript Biotech Corporation | -415.79 Million USD | 100.0% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | 100.0% |
| Anthera Pharmaceuticals, Inc. | - USD | NaN% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 100.0% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | 100.0% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 100.0% |
| Kadimastem Ltd | -3.04 Million USD | 100.0% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | 100.0% |
| VitaSpring Biomedical Co. Ltd. | - USD | NaN% |
| Capstone Therapeutics Corp. | -1.25 Million USD | 100.0% |
| BioStem Technologies, Inc. | -7.77 Million USD | 100.0% |
| Oncology Pharma Inc. | - USD | NaN% |
| Reve Technologies, Inc. | -181.48 Thousand USD | 100.0% |
| LadRx Corporation | -3.82 Million USD | 100.0% |
| Cell Source, Inc. | -4.32 Million USD | 100.0% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 100.0% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 100.0% |
| NovAccess Global Inc. | -2.46 Million USD | 100.0% |
| Affymax, Inc. | -15.04 Million USD | 100.0% |
| Itoco Inc. | -919.14 Thousand USD | 100.0% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 100.0% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 100.0% |
| Mobile Lads Corp. | -554.55 Thousand USD | 100.0% |
| CytoDyn Inc. | -18.05 Million USD | 100.0% |
| Claritas Pharmaceuticals, Inc. | - USD | NaN% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | 100.0% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | 100.0% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | 100.0% |
| SYBLEU INC | -149.18 Thousand USD | 100.0% |
| Advanced Proteome Therapeutics Corporation | - USD | NaN% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 100.0% |
| International Stem Cell Corporation | -663 Thousand USD | 100.0% |
| Bioxytran, Inc. | -3.82 Million USD | 100.0% |
| GlobeImmune, Inc. | - USD | NaN% |
| Predictive Technology Group, Inc. | - USD | NaN% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 100.0% |
| Cardax, Inc. | - USD | NaN% |
| VG Life Sciences Inc. | -20.34 Thousand USD | 100.0% |
| Kaleido Biosciences, Inc. | - USD | NaN% |
| Advaxis, Inc. | -36.26 Million USD | 100.0% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | 100.0% |
| Regnum Corp. | -735.83 Thousand USD | 100.0% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 100.0% |
| Neutra Corp. | -229.48 Thousand USD | 100.0% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 100.0% |
| PureTech Health plc | -146.19 Million USD | 100.0% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 100.0% |
| IXICO plc | -1.43 Million USD | 100.0% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 100.0% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 100.0% |
| CSL Limited | 3.81 Billion USD | 100.0% |
| Cellectis S.A. | -108.85 Million USD | 100.0% |